<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04896619</url>
  </required_header>
  <id_info>
    <org_study_id>NL75320.081.20</org_study_id>
    <nct_id>NCT04896619</nct_id>
  </id_info>
  <brief_title>Cholesterol Effects of Kori-tofu Proteins</brief_title>
  <acronym>CHOKO</acronym>
  <official_title>Cholesterol Effects of Kori-tofu Proteins</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Wageningen University and Research</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Asahimatsu Foods</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Wageningen University and Research</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is a randomized, cross-over, double-blind, controlled trial in which participants&#xD;
      with mildly elevated levels of cholesterol will receive two 4-week interventions (e.g.&#xD;
      kori-tofu or control), with a wash-out period of 4 weeks in between. During the intervention&#xD;
      periods, subjects will eat 3 slices of bread per day, representing a Kori-tofu dose of 34.5&#xD;
      grams or a matched reference. Fasting total and LDL cholesterol will be determined at the&#xD;
      start and end of each of the two intervention periods.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      There are several types of tofu, an example of a specific type of tofu is called Kori-tofu.&#xD;
      Kori-tofu literally means frozen tofu. The production process of Kori-tofu leads to the&#xD;
      formation of a higher high molecular weight fraction (HMF) content of the soy proteins.&#xD;
      Several studies describe the effects of Kofi-tofu on health. In this study the aim is to&#xD;
      investigate the effect of repetitive consumption of Kori-tofu on blood cholesterol levels and&#xD;
      other lipid metabolism related measures, in research subjects with mildly elevated levels of&#xD;
      cholesterol.&#xD;
&#xD;
      The primary objective is to assess the effect of repetitive consumption of Kori-tofu on blood&#xD;
      total and LDL cholesterol levels. The secondary objective is to assess the effect of&#xD;
      repetitive consumption of Kori-tofu on other markers of lipid metabolism, glucose metabolism&#xD;
      and blood pressure.&#xD;
&#xD;
      The study is a randomized, cross-over, double-blind, controlled trial in which participants&#xD;
      will receive two 4-week interventions (e.g. kori-tofu or control), with a wash-out period of&#xD;
      4 weeks in between. During the intervention periods, subjects will eat 3 slices of bread per&#xD;
      day, representing a Kori-tofu dose of 34.5 grams or a matched reference (whey protein, soy&#xD;
      oil and maltodextrin/cellulose). Research subjects will visit our research unit before and&#xD;
      after each intervention period for a test day. During these test days fasting blood samples&#xD;
      will be collected and blood pressure measurements will be performed.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">September 7, 2021</start_date>
  <completion_date type="Anticipated">December 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 7, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in total cholesterol levels</measure>
    <time_frame>0 weeks, 4 weeks, 8 weeks and 12 weeks</time_frame>
    <description>under fasting conditions</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in LDL cholesterol levels</measure>
    <time_frame>0 weeks, 4 weeks, 8 weeks and 12 weeks</time_frame>
    <description>under fasting conditions</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in HDL cholesterol levels</measure>
    <time_frame>0 weeks, 4 weeks, 8 weeks and 12 weeks</time_frame>
    <description>under fasting conditions</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in triglycerides levels</measure>
    <time_frame>0 weeks, 4 weeks, 8 weeks and 12 weeks</time_frame>
    <description>under fasting conditions</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in leptin levels</measure>
    <time_frame>0 weeks, 4 weeks, 8 weeks and 12 weeks</time_frame>
    <description>under fasting conditions</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in adiponectin levels</measure>
    <time_frame>0 weeks, 4 weeks, 8 weeks and 12 weeks</time_frame>
    <description>under fasting conditions</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in plasma insulin levels</measure>
    <time_frame>0 weeks, 4 weeks, 8 weeks and 12 weeks</time_frame>
    <description>under fasting conditions</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in HbA1c levels</measure>
    <time_frame>0 weeks, 4 weeks, 8 weeks and 12 weeks</time_frame>
    <description>under fasting conditions</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in fructosamine levels</measure>
    <time_frame>0 weeks, 4 weeks, 8 weeks and 12 weeks</time_frame>
    <description>under fasting conditions</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in glucose levels</measure>
    <time_frame>0 weeks, 4 weeks, 8 weeks and 12 weeks</time_frame>
    <description>under fasting conditions</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in systolic blood pressure levels</measure>
    <time_frame>0 weeks, 4 weeks, 8 weeks and 12 weeks</time_frame>
    <description>under fasting conditions</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in diastolic blood plessure levels</measure>
    <time_frame>0 weeks, 4 weeks, 8 weeks and 12 weeks</time_frame>
    <description>under fasting conditions</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">48</enrollment>
  <condition>Lipid Metabolism Disorders</condition>
  <arm_group>
    <arm_group_label>Daily dose of Kori-tofu mixed in 3 slices of bread</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Kori tofu as part of bread</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Daily dose of whey protein, soy oil and maltodextrin mixed in 3 slices of bread</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Whey protein, soy oil and maltodextrin as part of bread</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Kori tofu bread</intervention_name>
    <description>34.5 grams of Kori-tofu, mixed in 3 slices of wheat bread.</description>
    <arm_group_label>Daily dose of Kori-tofu mixed in 3 slices of bread</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Whey protein bread</intervention_name>
    <description>Matched whey protein, soy oil and maltodextrin/cellulose, mixed in 3 slices of wheat bread</description>
    <arm_group_label>Daily dose of whey protein, soy oil and maltodextrin mixed in 3 slices of bread</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age between 40-70 years;&#xD;
&#xD;
          -  BMI between 18.5-35 kg/m2;&#xD;
&#xD;
          -  Total cholesterol levels &gt;5 mmol/L or LDL &gt;3 mmol/L&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Use of medication/supplements/food items that may influence the study results, such as&#xD;
             cholesterol lowering medication, Becel ProActiv (judged by our research physician);&#xD;
&#xD;
          -  Total cholesterol levels &gt;7 mmol/L;&#xD;
&#xD;
          -  LDL cholesterol levels &gt;5 mmol/L;&#xD;
&#xD;
          -  Reported slimming, medically prescribed or other extreme diets;&#xD;
&#xD;
          -  Reported weight loss or weight gain of &gt;5 kg in the month prior to pre-study&#xD;
             screening;&#xD;
&#xD;
          -  Not willing to give up blood donation during the study;&#xD;
&#xD;
          -  Current smokers;&#xD;
&#xD;
          -  Alcohol intake â‰¥4 glasses of alcoholic beverages per day;&#xD;
&#xD;
          -  Pregnant, lactating or wishing to become pregnant in the period of the study&#xD;
             (self-reported);&#xD;
&#xD;
          -  Abuse of soft and/or hard drugs;&#xD;
&#xD;
          -  Food allergies or intolerances for products that we use in the study;&#xD;
&#xD;
          -  Participation in another clinical trial at the same time; NL75320.081.20 CHOKO Version&#xD;
             number: 4, April 2021 15 of 34&#xD;
&#xD;
          -  Being an employee of the Food, Health &amp; Consumer Research group of Wageningen Food &amp;&#xD;
             Biobased Research.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Diederik Esser, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Wageningen University &amp; Research</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Wageningen University &amp; Research</name>
      <address>
        <city>Wageningen</city>
        <state>Gelderland</state>
        <zip>6708 WG</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>May 10, 2021</study_first_submitted>
  <study_first_submitted_qc>May 20, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 21, 2021</study_first_posted>
  <last_update_submitted>September 9, 2021</last_update_submitted>
  <last_update_submitted_qc>September 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Wageningen University and Research</investigator_affiliation>
    <investigator_full_name>Diederik Esser</investigator_full_name>
    <investigator_title>Project leader clinical trials</investigator_title>
  </responsible_party>
  <keyword>Kori tofu</keyword>
  <keyword>Cholesterol</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metabolic Diseases</mesh_term>
    <mesh_term>Lipid Metabolism Disorders</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

